BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • Zydus Cadila Seeks Nod For First...
      Coronavirus

      Zydus Cadila Seeks Nod For First Needle Free Plasmid DNA COVID-19 Vaccine

      The indigenous vaccine is the first three-shot, plasmid DNA, needle free COVID-19 vaccine and has an efficacy of 66 percent

      By - Shachi Sutaria |
      Published -  2 July 2021 5:46 PM IST
    • Boomlive
      Zydus Cadila Seeks Nod For First Needle Free Plasmid DNA COVID-19 Vaccine

      Ahmedabad-based Zydus Cadila is seeking emergency use authorisation for its COVID-19 vaccine ZyCov-D from the Drug Control General of India after the company revealed that the vaccine showed 66.6 per cent efficacy against SARS-CoV-2. If approved, the vaccine will be the first of many including to use plasmid DNA and to be a needleless injectable vaccine.

      The indigenous vaccine is the first COVID-19 vaccine to use plasmid DNA as a technology platform against SARS-CoV-2. These plasmid DNA molecules emulate the spike protein of SARS-CoV-2 inside the body and push the body to elicit an immune response against it. While Oxford-AstraZeneca (Covishield), Sputnik V, and Johnson & Johnson vaccines use other viruses as vectors for the growth of the viral DNA, Pfizer and Moderna use mRNA, and Covaxin isolates and inactivates the original SARS-CoV-2.

      If approved, ZyCov-D will become the first vaccine to be approved for the 12-18 age group in India. The company, conducted a phase III trial with 28,000 participants at 50 sites and even included adolescents between the ages of 12-18 years of age.

      The vaccine is the only COVID-19 vaccine to be administered in three shots. Most of the other vaccines are to be administered in two shots while the vaccine produced by Johnson and Johnson is a one dose vaccine. Cadila Healthcare is also planning to study the effect of a two-dose vaccine against the virus and plans to manufacture close to 10-12 crore doses annually.

      ZyCoV-D, according to the company, can be easily adapted to deal with mutations, making the plasmid DNA platform a lucrative and easy to use technology. The vaccine has already exhibited significant immunogenicity and tolerability and safety as reported in the Phase I/II clinical trials.

      Furthermore, to reduce vaccine hesitancy among those who are afraid of using needles, this vaccine uses a needle free injection called PharmaJet which uses a spring to inject the vaccine in the intradermal area. This is another first which separates ZyCoV-D from the other COVID-19 vaccines.

      Also Read:Needle Phobia In Times Of Covid Vaccine: How To Cope With It?

      The plasmid DNA needs to be stored at 2º-8ºC. It was also found to be stable at 25ºC for three months. This stability makes it easier for the transportation of the vaccine as well as storing it before it is used.

      If approved, ZyCoV-D will become the fifth vaccine to receive EUA in the country. So far, only Covishield and Covaxin are currently being administered. Sputnik V has started its seven-day follow up for participants and is expected to roll out the vaccine, soon. Cipla will be importing the Moderna vaccine after it received approval on Tuesday.

      Also Read:DCGI Approves Moderna Vaccine, Cipla To Import


      Tags

      zydus cadilaCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!